OBJECTIVES: To describe the clinical characteristics and muscle pathological features of patients with systemic sclerosis (SSc) and myopathy and analyse their impact on muscle outcome. METHODS: Thirty-five patients with myopathy and available muscle biopsy were restrospectively investigated from the charts of four hospital centres. RESULTS: Twenty-six (74%) cases had diffuse SSc. The median time from SSc diagnosis was 5 years (range 0-23) at myopathy onset. The main myopathological features were mononuclear inflammation (63%), muscle atrophy (60%), necrosis (59%), regeneration (44%), fibrosis (24%) or microangiopathy (27%). After a median follow-up of 4.4 years, 24 patients (69%) showed complete or partial muscle remission. Only histological muscle inflammation was associated with good muscle prognosis in multivariate analysis (odds ratio 44.7, 95% CI 2.8 to 704.7). Patients without muscle inflammation had a poor response to corticosteroids (38% favourable response vs 90% in patients with inflammation). CONCLUSION: Muscle histopathology is critical in the therapeutic management of SSc-associated myopathy.
OBJECTIVES: To describe the clinical characteristics and muscle pathological features of patients with systemic sclerosis (SSc) and myopathy and analyse their impact on muscle outcome. METHODS: Thirty-five patients with myopathy and available muscle biopsy were restrospectively investigated from the charts of four hospital centres. RESULTS: Twenty-six (74%) cases had diffuse SSc. The median time from SSc diagnosis was 5 years (range 0-23) at myopathy onset. The main myopathological features were mononuclear inflammation (63%), muscle atrophy (60%), necrosis (59%), regeneration (44%), fibrosis (24%) or microangiopathy (27%). After a median follow-up of 4.4 years, 24 patients (69%) showed complete or partial muscle remission. Only histological muscle inflammation was associated with good muscle prognosis in multivariate analysis (odds ratio 44.7, 95% CI 2.8 to 704.7). Patients without muscle inflammation had a poor response to corticosteroids (38% favourable response vs 90% in patients with inflammation). CONCLUSION: Muscle histopathology is critical in the therapeutic management of SSc-associated myopathy.
Authors: Julie J Paik; Fredrick M Wigley; Thomas E Lloyd; Andrea M Corse; Livia Casciola-Rosen; Ami A Shah; Francesco Boin; Laura K Hummers; Andrew L Mammen Journal: Arthritis Care Res (Hoboken) Date: 2015-10 Impact factor: 4.794
Authors: Veronica Silva Vilela; Sergio Prieto-González; José C Milisenda; Albert Selva-O Callaghan; Josep M Grau Journal: Rheumatol Int Date: 2014-12-30 Impact factor: 2.631
Authors: Stefan Schanz; Jörg Henes; Anja Ulmer; Ina Kötter; Gerhard Fierlbeck; C D Claussen; Marius Horger Journal: Eur Radiol Date: 2012-07-29 Impact factor: 5.315
Authors: Ulrich A Walker; Philip J Clements; Yannick Allanore; Oliver Distler; Chester V Oddis; Dinesh Khanna; Daniel E Furst Journal: Rheumatology (Oxford) Date: 2017-09-01 Impact factor: 7.580
Authors: Sasan Partovi; Anja-Carina Schulte; Markus Aschwanden; Daniel Staub; Daniela Benz; Stephan Imfeld; Björn Jacobi; Pavel Broz; Kurt A Jäger; Martin Takes; Rolf W Huegli; Deniz Bilecen; Ulrich A Walker Journal: Arthritis Res Ther Date: 2012-10-04 Impact factor: 5.156